SANA

Sana Biotechnology Inc

Add to Watchlist

Advanced Chart

1.745

+0.035(+2.050%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

1.760

Open

1.740

VWAP

1.73

Vol

1.27M

Mkt Cap

393.59M

Low

1.670

Amount

2.21M

EV/EBITDA(TTM)

Total Shares

221.50M

281.00M

EV/OCF(TTM)

P/S(TTM)

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

5 Analyst Rating

329.80% Upside

Wall Street analysts forecast SANA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SANA is 7.50 USD with a low forecast of 5.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

329.80% Upside

Current: 1.745

Low

5.00

Averages

7.50

High

11.00

329.80% Upside

Current: 1.745

Low

5.00

Averages

7.50

High

11.00

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$11

2025-04-24

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$11

2025-04-24

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$11

2025-03-18

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$11

2025-03-18

Reiterates

Strong Buy

Reason

Citizens Capital Markets

Reni Benjamin

Hold

Buy

Upgrades

2025-03-18

Reason

Citizens Capital Markets

Reni Benjamin

Price Target

2025-03-18

Upgrades

Hold

Buy

Reason

Citizens JMP upgraded Sana Biotechnology to Outperform from Market Perform with a $5 price target. The firm cites its cash per share and platform value analysis for the upgrade. Sana reported Q4 results and provided corporate updates, including longer follow-up from the Upsala IST demonstrating three-month islet cell viability, the analyst tells investors in a research note. Citizens says that with three-month follow-up from the modified pancreatic islet cell IST program validating the Hypoimmune platform in type 1 diabetes, SC291 data in autoimmune diseases expected in 2025, and a cash position of $152.5M, Sana shares are undervalued.

Jefferies

Roger Song

Strong Buy

Initiates

2025-03-14

Reason

Jefferies

Roger Song

Price Target

2025-03-14

Initiates

Strong Buy

Reason

Jefferies analyst Roger Song initiated coverage of Sana Biotechnology with a Buy rating and $7 price target. Sana is a clinical stage biotech focused on bringing engineered cells as medicines to market by leveraging its proprietary hypo-immune editing platform, the analyst tells investors in a research note. The firm says the company has three assets in development for three different disease spaces. It models peak adjusted revenues of $2.8B.

TD Cowen

Marc Frahm

Hold

Strong Buy

Upgrades

n/a

2025-01-08

Reason

TD Cowen

Marc Frahm

Price Target

n/a

2025-01-08

Upgrades

Hold

Strong Buy

Reason

TD Cowen upgraded Sana Biotechnology to Buy from Hold without a price target. The company reported positive data indicating Hypoimmune modified cadaver islet cells sustained immune evasion/C-peptide production in a type 1 diabetes patient without immunosuppression, the analyst tells investors in a research note. The firm says this establishes proof of concept for Hypoimmune's immune evasion properties and "meaningfully derisks" type 1 diabetes and other applications. Much commercialization work remains ahead, but the company "now bears a meaningfully changed risk profile," contends TD.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Maintains

$8 → $11

2025-01-08

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$8 → $11

2025-01-08

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sana Biotechnology Inc (SANA.O) is -2.32, compared to its 5-year average forward P/E of -5.18. For a more detailed relative valuation and DCF analysis to assess Sana Biotechnology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.18

Current PE

-2.32

Overvalued PE

-1.62

Undervalued PE

-8.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.42

Current EV/EBITDA

-1.96

Overvalued EV/EBITDA

-0.29

Undervalued EV/EBITDA

-8.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

YoY :

-30.37%

-50.63M

Operating Profit

FY2025Q1

YoY :

-100.00%

N/A

Net Income after Tax

FY2025Q1

YoY :

-57.14%

-0.21

EPS - Diluted

FY2025Q1

YoY :

-40.11%

-48.79M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

1.9M

USD

6-9

Months

1.2M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 297.73% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

1.1M

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.8M

Volume

Months

6-9

0.0

Volume

Months

0-12

440.0K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

1.9M

USD

6-9

Months

1.2M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SANA News & Events

Events Timeline

2025-03-17 (ET)

2025-03-17

16:15:13

Sana Biotechnology reports Q4 EPS (21c), consensus (24c)

2025-01-07 (ET)

2025-01-07

15:09:14

Sana Biotechnology announces initial results from type 1 diabetes study

2024-12-02 (ET)

2024-12-02

08:08:34

Sana Biotechnology announces Fast Track designation for SC291

News

7.0

05:45 AMPRnewswire

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

7.0

05:12 AMGlobenewswire

Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA

7.0

05-15Globenewswire

SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit